Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine/carboplatin with or without thalidomide in advanced non-small cell lung cancer
ISRCTN77341241Phase 3Completed
- Sponsor
- London Lung Cancer Group
- Start
- Jan 2003
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Gemcitabine + carboplatin + thalidomide with Gemcitabine + carboplatin + placebo (2 arms). Started Jan 2003; status: completed.
02
Drugs
thalidomidegemcitabinecarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ISRCTN77341241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN77341241.